News Related to Unicycive Therapeutics

Related coverage linked through entity extraction aliases.

FDA Issues Complete Response Letter for Unicycive's Oxylanthanum Carbonate NDA Resubmission

Jun 30, 2026

Unicycive Therapeutics received an FDA Complete Response Letter for its oxylanthanum carbonate NDA resubmission due to third-party manufacturing deficiencies. The FDA raised no efficacy or safety concerns and requested no new data. Labeling discussions are ongoing.

2026 Healthcare Conferences Highlight AI Innovation and Cross-Border Care Trends

Jun 05, 2026

AI-driven innovation is reshaping healthcare, biotech, and life sciences, as highlighted at the 2026 Forbes Iconoclast Summit. The Global Medical Tourism & Insurance Summit will convene in Palm Beach, Florida, in May to address cross-border care solutions. The life sciences sector enters 2026 with regulatory acceleration and AI embedded across the industry.